吡仑帕奈治疗儿童癫痫的中国专家共识_Journal of Epilepsy

Authors：

 中国抗癫痫协会创新与转化专业委员会 , 中华医学会儿科学分会神经学组

执笔（按单位拼音和姓氏笔画排列，排名不分先后）季涛云、姜玉武（北京大学第一医院），操德智（深圳市儿童医院），陈旭勤（上海交通大学医学院附属儿童医院），方方（首都医科大学附属北京儿童医院），冯建华（浙江大学医学院附属第二医院），高峰、缪静（浙江大学医学院附属儿童医院），高丽（河南省人民医院），黄绍平（西安交通大学第二附属医院），蒋莉（重庆医科大学附属儿童医院），李霞（西安市儿童医院），刘晓鸣（徐州市儿童医院），刘雪雁（中国医科大学附属盛京医院），刘占利（杭州市儿童医院），罗蓉（四川大学华西第二医院），梅道启（苏州大学附属儿童医院），彭镜（中南大学湘雅医院），孙丹（武汉儿童医院），孙素真（河北省儿童医院），王艺（复旦大学附属儿科医院），吴春风（南京市儿童医院），张洪伟（山东大学附属儿童医院），张玉琴（天津市儿童医院），禚志红（郑州大学第一附属医院）;

Corresponding author：

中国抗癫痫协会创新与转化专业委员会, Email: jiangyuwu@bjmu.edu.cn

Keywords：

DOI：

10.7507/2096-0247.202506002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 中国抗癫痫协会创新与转化专业委员会, 中华医学会儿科学分会神经学组. 吡仑帕奈治疗儿童癫痫的中国专家共识. Journal of Epilepsy, 2025, 11(4): 277-287. doi: 10.7507/2096-0247.202506002 Copy

1.	Yu PM, Ding D, Zhu GX, et al. International bureau for epilepsy survey of children, teenagers, and young people with epilepsy: data in China. Epilepsy Behav, 2009, 16(1): 99-104.
2.	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2022, 102(10): 697-703.
3.	American Academy of Neurology. Clinical practice guideline process manual, 2011 Ed. St. Paul, 2011.
4.	Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J ClinEpidemiol, 2011, 64(4): 401-406.
5.	Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: going from evidence to recommendation determinants of a recommendation's direction and strength. J Clin Epidemiol, 2013, 66(7): 726-735.
6.	中国抗癫痫协会. 临床诊疗指南-癫痫病分册(2023修订版). 北京: 人民卫生出版社, 2023.
7.	Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia, 2025, 00: 1-20. Online ahead of print.
8.	Potschka H, Trinka E. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60(Suppl 1): 22-36.
9.	Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol, 2023, 14: 1182304.
10.	Wang T, Li L, Sun F, et al. Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis. Int J Neurosci, 2023, 133(9): 1008-1016.
11.	Flamini R, Fogarasi A, Omatsu H, et al. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal-onset seizures or generalized tonic-clonic seizures. Epilepsia, 2025, 66(4): 1097-1109.
12.	Ji TY, Ding YF, Zhang YQ, et al. Investigation of efficacy, safety and tolerability of perampanel monotherapy in children with newly-diagnosed epilepsy in routine clinical practice in China: a multicenter prospective observational study. World J Pediatr, 2025. Online ahead of print.
13.	Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalized seizures. CNS Drugs, 2021, 35(8): 821-837.
14.	Fan PF, Zhuo C, Huang M. Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies. Eur Rev Med Pharmacol Sci, 2023, 27(13): 6027-6039.
15.	Toledano Delgado R, García-Morales I, Parejo-Carbonell B, et al. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry. Epilepsia, 2020, 61(6): 1109-1119.
16.	Fujimoto A, Enoki H, Hatano K, et al. Replacement of valproic acid with new anti-seizure medications in idiopathic generalized epilepsy. J Clin Med, 2022, 11(15): 4582.
17.	Mir A, Alghamdi A, Alotaibi W, et al. A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus. Epileptic Disord, 2022, 24(4): 633-646.
18.	Wang XH, Ji TY, Liu MM, et al. Effectiveness and safety of perampanel for pediatric patients with epilepsy: a real-world study from China. Pediatric Investigation, 2025, 00: 1-9. Online ahead of print.
19.	马湖萍, 任蓉, 侯梅, 等. 新型抗癫痫发作药物吡仑帕奈添加治疗0~18岁儿童难治性癫痫的临床观察研究. 中国全科医学, 2025, 28(2): 250-256.
20.	Qu R, Dai Y, Chen X, et al. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study. Epileptic Disord, 2021, 23(6): 854-864.
21.	Chang FM, Fan PC, Weng WC, et al. The efﬁcacy of perampanel in young children with drugresistant epilepsy. Seizure, 2020, 75: 82-86.
22.	张捷, 谢涵, 邓泂, 等. 基于随访 6 个月疗效结局的加用吡仑帕奈治疗儿童药物难治性癫的单中心前瞻性队列研究. 中国循证儿科杂志, 2021, 16(4): 269-274.
23.	Alyazidi AS, Muthaffar OY, Bamaga AK, et al. The therapeutic role of perampanel in treating pediatric patients with dravet syndrome: a scoping review. Cureus, 2024, 16(7): e65017.
24.	中国抗癫痫协会创新与转化专业委员会, 中华医学会儿科学分会罕见病学组, 中华医学会儿科学分会神经学组. Dravet 综合征诊断与治疗的中国专家共识. 癫痫杂志, 2024, 10(1): 1-11.
25.	Nissenkorn A, Kluger G, Schubert-Bast S, et al. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia, 2023, 64(4): 866-74.
26.	Muthaffar OY, Bamaga AK, Alyazidi AS, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Transl Pediatr, 2024, 13(4): 584-595.
27.	Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Epilepsy Res, 2019, 154: 34-38.
28.	Lin KL, Lin JJ, Chou ML, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav, 2018, 85: 188-94.
29.	Qu R, Dai Y, Qu X, et al. Use of perampanel in children with refractory epilepsy of genetic aetiology. Epileptic Disord, 2022, 24(4): 687-695.
30.	Miao P, Zhu X, Jin W, et al. Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology. Ann Clin Transl Neurol, 2023, 10(8): 1374-1382.
31.	中国抗癫痫协会创新与转化专委会. Lennox-Gastaut 综合征诊断治疗的中国专家共识. 癫痫杂志, 2022, 8(3): 187-195.
32.	Vossler DG, Porter BE, Kira R, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: a randomized tria l. Epilepsia, 2025, 66(2): 379-393.
33.	Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav, 2017, 74: 59-63.
34.	Matricardi S, Cesaroni E, Bonanni P, et al. Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. Epilepsia, 2023, 64(6): e98-e104.
35.	Alonso-Singer P, Aguilar-Amat Prior MJ, Oliva-Navarro J, et al. Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice. Epilepsy Behav, 2022, 134: 108836.
36.	Matsuura R, Hamano SI, Ikemoto S, et al. Adjunctive perampanel therapy for patients with epileptic spasms. Pediatr Int, 2022, 64(1): e15364.
37.	Li X, Gao K, Li Y, et al. Effective treatment of NR2F1-related epilepsy with perampanel. Acta Epileptologica, 2024, 6(1): 3.
38.	Sanlidag B, Köken ÖY, Temel EÜ, et al. Benign epilepsy with centrotemporal spikes: is there a thalamocortical network dysfunction present? Seizure, 2020, 79: 44-48.
39.	Yue X, Liu XM, Chen J, et al. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat, 2023, 19: 1263-1271.
40.	岳璇, 刘晓鸣, 陈娇, 等. 吡仑帕奈单药治疗伴中央颞区棘波的自限性癫痫疗效观察及安全性研究. 癫痫杂志, 2023, 9(5): 388-392.
41.	闫婷, 杜丽君, 李晓媛, 等. 吡仑帕奈单药和添加治疗儿童癫痫伴睡眠中癫痫性电持续状态的疗效及安全性研究. 实用药物与临床, 2024, 27(9): 668-672.
42.	Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia, 2022, 63(6): 1475-1499.
43.	Brandt C, Wechsler RT, O'Brien TJ, et al. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure, 2020, 80: 115-123.
44.	Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia, 2018, 59(9): 1740-1752.
45.	Operto FF, Orsini A, Sica G, et al. Perampanel and childhood absence epilepsy: a real life experience. Front Neurol, 2022, 13: 952900.
46.	Montoya Gutiérrez FJ, Díaz Román M, Cerveró Albert D. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment. Epilepsy Res, 2020, 165: 106378.
47.	Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav, 2016, 61: 41-45.
48.	Mai J, Li H, He Y, et al. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study. Seizure, 2024, 117: 44-49.
49.	易珈沁, 孙丹. 吡仑帕奈添加治疗儿童癫痫疗效及安全性: 一项单中心回顾性观察性研究. 中国实用儿科杂志, 2024, 39(10): 779-784.
50.	Lim GY, Chen CL, Chan Wei Shih D. Utility and safety of perampanel in pediatric FIRES and other drug-resistant epilepsies. Child Neurol Open, 2021, 8: 2329048X211055335.
51.	Sokka A, Olsen P, Kirjavainen J, et al. Etiology, syndrome diagnosis, and cognition in childhood‐onset epilepsy: a population‐based study. Epilepsia Open, 2017, 2(1): 76-83.
52.	Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology, 2017, 89(9): 893-899.
53.	Bosch DG, Boonstra FN, Gonzaga-Jauregui C, et al. NR2F1 mutations cause optic atrophy with intellectual disability. Am J Hum Genet, 2014, 94(2): 303-309.
54.	Chen CA, Bosch DG, Cho MT, et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med, 2016, 18(11): 1143-1150.
55.	Wang T, Wang J, Dou Y, et al. Clinical characteristics and prognosis in a large paediatric cohort with status epilepticus. Seizure, 2020, 80: 5-11.
56.	儿童癫痫持续状态协作组. 儿童癫痫持续状态诊断治疗的中国专家共识(2022). 癫痫杂志, 2022, 8(5): 383-389.
57.	Perez DQ, Espiritu AI, Jamora RDG. Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav, 2022, 128: 108583.
58.	Wachiropathum P, Nabangchang C, Likasitthananon N, et al. Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand. Epilepsy Behav, 2021, 118: 107964.
59.	关月, 张筱芳, 牟菲, 等. 新型抗癫痫药吡仑帕奈治疗儿童癫痫持续状态4例并文献复习. 中国医院药学杂志, 2021, 41(16): 1680-1682.
60.	Nobili L, Beniczky S, Eriksson SH, et al. Expert opinion: managing sleep disturbances in people with epilepsy. Epilepsy Behav, 2021, 124: 108341.
61.	Xu S, Xu ZY, Zheng Y, et al. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures: A real-world experience in eastern China. Seizure, 2023, 110: 231-237.
62.	Wang Q, Xu Y, Chen Y, et al. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study. Epilepsy Behav, 2022, 136: 108937.
63.	Kanemura H, Sano F, Hoshino H, et al. Efficacy of perampanel in epilepsy patients with autism spectrum disorder. Epilepsy Res, 2021, 170: 106550.
64.	Gupta S, Hwang Y, Ludwig N, et al. Case report: Off-label use of low-dose perampanel in a 25-month-old girl with a pathogenic SYNGAP1 variant. Front Neurol, 2023, 14: 1221161.
65.	Scorrano G, Lattanzi S, Salpietro V, et al. The cognitive and behavioural effects of perampanel in children with neurodevelopmental disorders: a systematic review. J Clin Med, 2024, 13(2): 372.
66.	Witt JA, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure, 2022, 94: 107-111.
67.	Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav, 2017, 66: 64-67.
68.	Coombs ID, Ziobro J, Krotov V, et al. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures: functional characterization and targeted treatmen. Epilepsia, 2022, 63(12): e156-e163.
69.	吴晔, 操德智, 冯建华, 等. 儿童癫痫患者中吡仑帕奈使用的专家建议. 癫痫杂志, 2022, 8(2): 95-4576.
70.	Lee WT, Chan DWS, Gulati S, et al. Role of perampanel in the management of pediatric epilepsies in Asia: expert opinion. Pediatr Neurol, 2024, 151: 5-16.
71.	Lavu A, Aboulatta L, Abou-Setta AM, et al. Efficacy and safety of perampanel in epilepsy: a systematic review and meta-analysis of randomised controlled trials. Seizure, 2022, 102: 54-60.
72.	Sun S, Li X, Liu X. Eﬃcacy, tolerability and safety of perampanel in children and adolescents with epilepsy: Systematic review and meta-analysis. Brain Dev, 2023, 45(5): 260-269.
73.	Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728.
74.	Ikemoto S, Hamano S, Hirata Y, et al. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure, 2019, 73: 75-78.
75.	Chung S, Williams B, Dobrinsky C, et al. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav, 2017, 75: 79-85.
76.	Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs, 2013, 27(10): 817-827.
77.	Hou LY, Yang JJ, Zhang X, et al. Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: a systematic review and meta-analysis. Front Pharmacol, 2023, 14: 1139514.
78.	Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol, 2016, 12(2): 106-116.
79.	Kanemura H, Sano F, Aihara M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur J Paediatr Neurol, 2019, 23(1): 197-203.
80.	Eisai Co. , Ltd (per FDA). Perampanel label. 2023.
81.	Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
82.	Renfroe JB, Mintz M, Davis R, et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efﬁcacy. J Child Neurol, 2019, 34(5): 284-294.
83.	Wang H, Wang J, Lin B, et al. Effect of Age, Comedications, and CYP3A4/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy. J Clin Pharmacol, 2024, 64(6): 737-743.
84.	Li Y, Dong N, Qin YX, et al. Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration-to-dose ratio. Epilepsia Open, 2022, 7(4): 737-746.
85.	Zhao T, Li HJ, Zhang HL, et al. Effects of CYP3A4 genetic polymorphisms on the pharmacokinetics and efficacy of perampanel in Chinese pediatric patients with epilepsy. Seizure, 2024, 120: 142-149.
86.	Zhao T, Feng JR, Zhang HL, et al. Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy. Pharmacogenet Genomics, 2024, 34(6): 184-190.
87.	Yamamoto Y, Shiratani Y, Asai S, et al. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. Seizure, 2020, 83: 181-186.
88.	Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia, 2015, 56(1): 12-27.
89.	Yamamoto Y, Usui N, Nishida T, et al. Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs. Therapeutic Drug Monitoring, 2017, 39(4): 446-449.
90.	Ishikawa N, Tateishi Y, Tani H, et al. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Epilepsy Behav, 2019, 94: 82-86.
91.	Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7): 1239-1276.

1. Yu PM, Ding D, Zhu GX, et al. International bureau for epilepsy survey of children, teenagers, and young people with epilepsy: data in China. Epilepsy Behav, 2009, 16(1): 99-104.
2. 陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版). 中华医学杂志, 2022, 102(10): 697-703.
3. American Academy of Neurology. Clinical practice guideline process manual, 2011 Ed. St. Paul, 2011.
4. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J ClinEpidemiol, 2011, 64(4): 401-406.
5. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: going from evidence to recommendation determinants of a recommendation's direction and strength. J Clin Epidemiol, 2013, 66(7): 726-735.
6. 中国抗癫痫协会. 临床诊疗指南-癫痫病分册(2023修订版). 北京: 人民卫生出版社, 2023.
7. Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia, 2025, 00: 1-20. Online ahead of print.
8. Potschka H, Trinka E. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60(Suppl 1): 22-36.
9. Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol, 2023, 14: 1182304.
10. Wang T, Li L, Sun F, et al. Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis. Int J Neurosci, 2023, 133(9): 1008-1016.
11. Flamini R, Fogarasi A, Omatsu H, et al. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal-onset seizures or generalized tonic-clonic seizures. Epilepsia, 2025, 66(4): 1097-1109.
12. Ji TY, Ding YF, Zhang YQ, et al. Investigation of efficacy, safety and tolerability of perampanel monotherapy in children with newly-diagnosed epilepsy in routine clinical practice in China: a multicenter prospective observational study. World J Pediatr, 2025. Online ahead of print.
13. Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalized seizures. CNS Drugs, 2021, 35(8): 821-837.
14. Fan PF, Zhuo C, Huang M. Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies. Eur Rev Med Pharmacol Sci, 2023, 27(13): 6027-6039.
15. Toledano Delgado R, García-Morales I, Parejo-Carbonell B, et al. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry. Epilepsia, 2020, 61(6): 1109-1119.
16. Fujimoto A, Enoki H, Hatano K, et al. Replacement of valproic acid with new anti-seizure medications in idiopathic generalized epilepsy. J Clin Med, 2022, 11(15): 4582.
17. Mir A, Alghamdi A, Alotaibi W, et al. A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus. Epileptic Disord, 2022, 24(4): 633-646.
18. Wang XH, Ji TY, Liu MM, et al. Effectiveness and safety of perampanel for pediatric patients with epilepsy: a real-world study from China. Pediatric Investigation, 2025, 00: 1-9. Online ahead of print.
19. 马湖萍, 任蓉, 侯梅, 等. 新型抗癫痫发作药物吡仑帕奈添加治疗0~18岁儿童难治性癫痫的临床观察研究. 中国全科医学, 2025, 28(2): 250-256.
20. Qu R, Dai Y, Chen X, et al. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study. Epileptic Disord, 2021, 23(6): 854-864.
21. Chang FM, Fan PC, Weng WC, et al. The efﬁcacy of perampanel in young children with drugresistant epilepsy. Seizure, 2020, 75: 82-86.
22. 张捷, 谢涵, 邓泂, 等. 基于随访 6 个月疗效结局的加用吡仑帕奈治疗儿童药物难治性癫的单中心前瞻性队列研究. 中国循证儿科杂志, 2021, 16(4): 269-274.
23. Alyazidi AS, Muthaffar OY, Bamaga AK, et al. The therapeutic role of perampanel in treating pediatric patients with dravet syndrome: a scoping review. Cureus, 2024, 16(7): e65017.
24. 中国抗癫痫协会创新与转化专业委员会, 中华医学会儿科学分会罕见病学组, 中华医学会儿科学分会神经学组. Dravet 综合征诊断与治疗的中国专家共识. 癫痫杂志, 2024, 10(1): 1-11.
25. Nissenkorn A, Kluger G, Schubert-Bast S, et al. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia, 2023, 64(4): 866-74.
26. Muthaffar OY, Bamaga AK, Alyazidi AS, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Transl Pediatr, 2024, 13(4): 584-595.
27. Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Epilepsy Res, 2019, 154: 34-38.
28. Lin KL, Lin JJ, Chou ML, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav, 2018, 85: 188-94.
29. Qu R, Dai Y, Qu X, et al. Use of perampanel in children with refractory epilepsy of genetic aetiology. Epileptic Disord, 2022, 24(4): 687-695.
30. Miao P, Zhu X, Jin W, et al. Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology. Ann Clin Transl Neurol, 2023, 10(8): 1374-1382.
31. 中国抗癫痫协会创新与转化专委会. Lennox-Gastaut 综合征诊断治疗的中国专家共识. 癫痫杂志, 2022, 8(3): 187-195.
32. Vossler DG, Porter BE, Kira R, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: a randomized tria l. Epilepsia, 2025, 66(2): 379-393.
33. Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav, 2017, 74: 59-63.
34. Matricardi S, Cesaroni E, Bonanni P, et al. Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. Epilepsia, 2023, 64(6): e98-e104.
35. Alonso-Singer P, Aguilar-Amat Prior MJ, Oliva-Navarro J, et al. Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice. Epilepsy Behav, 2022, 134: 108836.
36. Matsuura R, Hamano SI, Ikemoto S, et al. Adjunctive perampanel therapy for patients with epileptic spasms. Pediatr Int, 2022, 64(1): e15364.
37. Li X, Gao K, Li Y, et al. Effective treatment of NR2F1-related epilepsy with perampanel. Acta Epileptologica, 2024, 6(1): 3.
38. Sanlidag B, Köken ÖY, Temel EÜ, et al. Benign epilepsy with centrotemporal spikes: is there a thalamocortical network dysfunction present? Seizure, 2020, 79: 44-48.
39. Yue X, Liu XM, Chen J, et al. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat, 2023, 19: 1263-1271.
40. 岳璇, 刘晓鸣, 陈娇, 等. 吡仑帕奈单药治疗伴中央颞区棘波的自限性癫痫疗效观察及安全性研究. 癫痫杂志, 2023, 9(5): 388-392.
41. 闫婷, 杜丽君, 李晓媛, 等. 吡仑帕奈单药和添加治疗儿童癫痫伴睡眠中癫痫性电持续状态的疗效及安全性研究. 实用药物与临床, 2024, 27(9): 668-672.
42. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia, 2022, 63(6): 1475-1499.
43. Brandt C, Wechsler RT, O'Brien TJ, et al. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure, 2020, 80: 115-123.
44. Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia, 2018, 59(9): 1740-1752.
45. Operto FF, Orsini A, Sica G, et al. Perampanel and childhood absence epilepsy: a real life experience. Front Neurol, 2022, 13: 952900.
46. Montoya Gutiérrez FJ, Díaz Román M, Cerveró Albert D. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment. Epilepsy Res, 2020, 165: 106378.
47. Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav, 2016, 61: 41-45.
48. Mai J, Li H, He Y, et al. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study. Seizure, 2024, 117: 44-49.
49. 易珈沁, 孙丹. 吡仑帕奈添加治疗儿童癫痫疗效及安全性: 一项单中心回顾性观察性研究. 中国实用儿科杂志, 2024, 39(10): 779-784.
50. Lim GY, Chen CL, Chan Wei Shih D. Utility and safety of perampanel in pediatric FIRES and other drug-resistant epilepsies. Child Neurol Open, 2021, 8: 2329048X211055335.
51. Sokka A, Olsen P, Kirjavainen J, et al. Etiology, syndrome diagnosis, and cognition in childhood‐onset epilepsy: a population‐based study. Epilepsia Open, 2017, 2(1): 76-83.
52. Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology, 2017, 89(9): 893-899.
53. Bosch DG, Boonstra FN, Gonzaga-Jauregui C, et al. NR2F1 mutations cause optic atrophy with intellectual disability. Am J Hum Genet, 2014, 94(2): 303-309.
54. Chen CA, Bosch DG, Cho MT, et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med, 2016, 18(11): 1143-1150.
55. Wang T, Wang J, Dou Y, et al. Clinical characteristics and prognosis in a large paediatric cohort with status epilepticus. Seizure, 2020, 80: 5-11.
56. 儿童癫痫持续状态协作组. 儿童癫痫持续状态诊断治疗的中国专家共识(2022). 癫痫杂志, 2022, 8(5): 383-389.
57. Perez DQ, Espiritu AI, Jamora RDG. Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav, 2022, 128: 108583.
58. Wachiropathum P, Nabangchang C, Likasitthananon N, et al. Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand. Epilepsy Behav, 2021, 118: 107964.
59. 关月, 张筱芳, 牟菲, 等. 新型抗癫痫药吡仑帕奈治疗儿童癫痫持续状态4例并文献复习. 中国医院药学杂志, 2021, 41(16): 1680-1682.
60. Nobili L, Beniczky S, Eriksson SH, et al. Expert opinion: managing sleep disturbances in people with epilepsy. Epilepsy Behav, 2021, 124: 108341.
61. Xu S, Xu ZY, Zheng Y, et al. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures: A real-world experience in eastern China. Seizure, 2023, 110: 231-237.
62. Wang Q, Xu Y, Chen Y, et al. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study. Epilepsy Behav, 2022, 136: 108937.
63. Kanemura H, Sano F, Hoshino H, et al. Efficacy of perampanel in epilepsy patients with autism spectrum disorder. Epilepsy Res, 2021, 170: 106550.
64. Gupta S, Hwang Y, Ludwig N, et al. Case report: Off-label use of low-dose perampanel in a 25-month-old girl with a pathogenic SYNGAP1 variant. Front Neurol, 2023, 14: 1221161.
65. Scorrano G, Lattanzi S, Salpietro V, et al. The cognitive and behavioural effects of perampanel in children with neurodevelopmental disorders: a systematic review. J Clin Med, 2024, 13(2): 372.
66. Witt JA, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure, 2022, 94: 107-111.
67. Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav, 2017, 66: 64-67.
68. Coombs ID, Ziobro J, Krotov V, et al. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures: functional characterization and targeted treatmen. Epilepsia, 2022, 63(12): e156-e163.
69. 吴晔, 操德智, 冯建华, 等. 儿童癫痫患者中吡仑帕奈使用的专家建议. 癫痫杂志, 2022, 8(2): 95-4576.
70. Lee WT, Chan DWS, Gulati S, et al. Role of perampanel in the management of pediatric epilepsies in Asia: expert opinion. Pediatr Neurol, 2024, 151: 5-16.
71. Lavu A, Aboulatta L, Abou-Setta AM, et al. Efficacy and safety of perampanel in epilepsy: a systematic review and meta-analysis of randomised controlled trials. Seizure, 2022, 102: 54-60.
72. Sun S, Li X, Liu X. Eﬃcacy, tolerability and safety of perampanel in children and adolescents with epilepsy: Systematic review and meta-analysis. Brain Dev, 2023, 45(5): 260-269.
73. Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728.
74. Ikemoto S, Hamano S, Hirata Y, et al. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure, 2019, 73: 75-78.
75. Chung S, Williams B, Dobrinsky C, et al. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav, 2017, 75: 79-85.
76. Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs, 2013, 27(10): 817-827.
77. Hou LY, Yang JJ, Zhang X, et al. Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: a systematic review and meta-analysis. Front Pharmacol, 2023, 14: 1139514.
78. Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol, 2016, 12(2): 106-116.
79. Kanemura H, Sano F, Aihara M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur J Paediatr Neurol, 2019, 23(1): 197-203.
80. Eisai Co. , Ltd (per FDA). Perampanel label. 2023.
81. Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
82. Renfroe JB, Mintz M, Davis R, et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efﬁcacy. J Child Neurol, 2019, 34(5): 284-294.
83. Wang H, Wang J, Lin B, et al. Effect of Age, Comedications, and CYP3A4/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy. J Clin Pharmacol, 2024, 64(6): 737-743.
84. Li Y, Dong N, Qin YX, et al. Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration-to-dose ratio. Epilepsia Open, 2022, 7(4): 737-746.
85. Zhao T, Li HJ, Zhang HL, et al. Effects of CYP3A4 genetic polymorphisms on the pharmacokinetics and efficacy of perampanel in Chinese pediatric patients with epilepsy. Seizure, 2024, 120: 142-149.
86. Zhao T, Feng JR, Zhang HL, et al. Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy. Pharmacogenet Genomics, 2024, 34(6): 184-190.
87. Yamamoto Y, Shiratani Y, Asai S, et al. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. Seizure, 2020, 83: 181-186.
88. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia, 2015, 56(1): 12-27.
89. Yamamoto Y, Usui N, Nishida T, et al. Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs. Therapeutic Drug Monitoring, 2017, 39(4): 446-449.
90. Ishikawa N, Tateishi Y, Tani H, et al. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Epilepsy Behav, 2019, 94: 82-86.
91. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7): 1239-1276.

Previous Article
2025 年 4 期封面
Next Article
经皮耳迷走神经刺激治疗成人癫痫及精神共患病的专家共识

Journal of Epilepsy

吡仑帕奈治疗儿童癫痫的中国专家共识

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content